Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
1.
Commun Biol ; 4(1): 1091, 2021 09 16.
Artículo en Inglés | MEDLINE | ID: mdl-34531530

RESUMEN

During breast cancer metastasis, cancer cell invasion is driven by actin-rich protrusions called invadopodia, which mediate the extracellular matrix degradation required for the success of the invasive cascade. In this study, we demonstrate that TC10, a member of a Cdc42 subfamily of p21 small GTPases, regulates the membrane type 1 matrix metalloproteinase (MT1-MMP)-driven extracellular matrix degradation at invadopodia. We show that TC10 is required for the plasma membrane surface exposure of MT1-MMP at these structures. By utilizing our Förster resonance energy transfer (FRET) biosensor, we demonstrate the p190RhoGAP-dependent regulation of spatiotemporal TC10 activity at invadopodia. We identified a pathway that regulates invadopodia-associated TC10 activity and function through the activation of p190RhoGAP and the downstream interacting effector Exo70. Our findings reveal the role of a previously unknown regulator of vesicular fusion at invadopodia, TC10 GTPase, in breast cancer invasion and metastasis.


Asunto(s)
Neoplasias de la Mama/patología , Neoplasias Mamarias Animales/patología , Invasividad Neoplásica/genética , Metástasis de la Neoplasia/genética , Proteínas de Unión al GTP rho/genética , Adenocarcinoma , Animales , Neoplasias de la Mama/secundario , Línea Celular Tumoral , Femenino , Humanos , Neoplasias Mamarias Animales/secundario , Metaloproteinasa 14 de la Matriz/genética , Metaloproteinasa 14 de la Matriz/metabolismo , Ratones SCID , Ratas , Proteínas de Unión al GTP rho/metabolismo
2.
Mol Oncol ; 14(3): 520-538, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-31930767

RESUMEN

Breast cancer brain metastases (BCBMs) have been underinvestigated despite their high incidence and poor outcome. MicroRNAs (miRNAs), and particularly circulating miRNAs, regulate multiple cellular functions, and their deregulation has been reported in different types of cancer and metastasis. However, their signature in plasma along brain metastasis development and their relevant targets remain undetermined. Here, we used a mouse model of BCBM and next-generation sequencing (NGS) to establish the alterations in circulating miRNAs during brain metastasis formation and development. We further performed bioinformatics analysis to identify their targets with relevance in the metastatic process. We additionally analyzed human resected brain metastasis samples of breast cancer patients for target expression validation. Breast cancer cells were injected in the carotid artery of mice to preferentially induce metastasis in the brain, and samples were collected at different timepoints (5 h, 3, 7, and 10 days) to follow metastasis development in the brain and in peripheral organs. Metastases were detected from 7 days onwards, mainly in the brain. NGS revealed a deregulation of circulating miRNA profile during BCBM progression, rising from 18% at 3 days to 30% at 10 days following malignant cells' injection. Work was focused on those altered prior to metastasis detection, among which were miR-802-5p and miR-194-5p, whose downregulation was validated by qPCR. Using targetscan and diana tools, the transcription factor myocyte enhancer factor 2C (MEF2C) was identified as a target for both miRNAs, and its expression was increasingly observed in malignant cells along brain metastasis development. Its upregulation was also observed in peritumoral astrocytes pointing to a role of MEF2C in the crosstalk between tumor cells and astrocytes. MEF2C expression was also observed in human BCBM, validating the observation in mouse. Collectively, downregulation of circulating miR-802-5p and miR-194-5p appears as a precocious event in BCBM and MEF2C emerges as a new player in brain metastasis development.


Asunto(s)
Neoplasias Encefálicas/secundario , Neoplasias de la Mama/metabolismo , Neoplasias Mamarias Animales/sangre , MicroARNs/metabolismo , Animales , Astrocitos/metabolismo , Astrocitos/patología , Biomarcadores de Tumor/genética , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/metabolismo , Neoplasias de la Mama/genética , Neoplasias de la Mama/patología , Línea Celular Tumoral , Biología Computacional , Progresión de la Enfermedad , Regulación hacia Abajo , Femenino , Regulación Neoplásica de la Expresión Génica/genética , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Factores de Transcripción MEF2/genética , Factores de Transcripción MEF2/metabolismo , Neoplasias Mamarias Animales/genética , Neoplasias Mamarias Animales/patología , Neoplasias Mamarias Animales/secundario , Ratones , Ratones Endogámicos BALB C , MicroARNs/genética , Regulación hacia Arriba , Ensayos Antitumor por Modelo de Xenoinjerto
3.
Vet Clin Pathol ; 47(1): 142-145, 2018 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-29360147

RESUMEN

A 6-year-old female neutered European Shorthair cat was presented with a 2-day history of lethargy and hyporexia. On physical examination, the cat was slightly depressed and had a 2.5 cm nodule in the left 3rd mammary gland. The hemogram revealed mild leukocytosis with mature neutrophilia and moderate thrombocytopenia. On blood smear evaluation, rare pleomorphic cells, possibly of epithelial origin, were observed mainly at the feathered edge. The animal died about 12 hours after presentation, and a necropsy was performed. On histopathology, the mammary nodule was diagnosed as a tubulopapillary adenocarcinoma with vascular invasion and widespread metastases. Immunocytochemical tests for cytokeratins (AE1/AE3) confirmed the epithelial phenotype of the neoplastic cells observed on the blood smear. The present report describes a feline mammary carcinoma with widespread metastases and the presence of malignant epithelial cells in the peripheral blood referred to as carcinocythemia. This condition has been previously described in people and dogs. To the author's knowledge, this is the first reported case of feline carcinocythemia. As in other species, the phenomenon was associated with a terminal phase of systemic malignancy.


Asunto(s)
Carcinoma/veterinaria , Enfermedades de los Gatos/diagnóstico , Leucemia/veterinaria , Neoplasias Mamarias Animales/secundario , Animales , Carcinoma/patología , Carcinoma/secundario , Enfermedades de los Gatos/patología , Gatos , Femenino , Leucemia/patología , Neoplasias Mamarias Animales/metabolismo , Neoplasias Mamarias Animales/patología
4.
Elife ; 62017 12 21.
Artículo en Inglés | MEDLINE | ID: mdl-29266001

RESUMEN

Metastasis depends upon cancer cell growth and survival within the metastatic niche. Tumors which remodel their glycocalyces, by overexpressing bulky glycoproteins like mucins, exhibit a higher predisposition to metastasize, but the role of mucins in oncogenesis remains poorly understood. Here we report that a bulky glycocalyx promotes the expansion of disseminated tumor cells in vivo by fostering integrin adhesion assembly to permit G1 cell cycle progression. We engineered tumor cells to display glycocalyces of various thicknesses by coating them with synthetic mucin-mimetic glycopolymers. Cells adorned with longer glycopolymers showed increased metastatic potential, enhanced cell cycle progression, and greater levels of integrin-FAK mechanosignaling and Akt signaling in a syngeneic mouse model of metastasis. These effects were mirrored by expression of the ectodomain of cancer-associated mucin MUC1. These findings functionally link mucinous proteins with tumor aggression, and offer a new view of the cancer glycocalyx as a major driver of disease progression.


Asunto(s)
Carcinogénesis , Ciclo Celular , Proliferación Celular , Glicocálix/metabolismo , Neoplasias Mamarias Animales/secundario , Animales , Línea Celular Tumoral , Modelos Animales de Enfermedad , Glicocálix/genética , Humanos , Ratones , Mucina-1/genética , Mucina-1/metabolismo
5.
Cancer Res ; 77(2): 247-256, 2017 01 15.
Artículo en Inglés | MEDLINE | ID: mdl-28069800

RESUMEN

Recent advances in animal modeling, imaging technology, and functional genomics have permitted precise molecular observations of the metastatic process. However, a comprehensive understanding of the premetastatic niche remains elusive, owing to the limited tools that can map subtle differences in molecular mediators in organ-specific microenvironments. Here, we report the ability to detect premetastatic changes in the lung microenvironment, in response to primary breast tumors, using a combination of metastatic mouse models, Raman spectroscopy, and multivariate analysis of consistent patterns in molecular expression. We used tdTomato fluorescent protein expressing MDA-MB-231 and MCF-7 cells of high and low metastatic potential, respectively, to grow orthotopic xenografts in athymic nude mice and allow spontaneous dissemination from the primary mammary fat pad tumor. Label-free Raman spectroscopic mapping was used to record the molecular content of premetastatic lungs. These measurements show reliable distinctions in vibrational features, characteristic of the collageneous stroma and its cross-linkers as well as proteoglycans, which uniquely identify the metastatic potential of the primary tumor by recapitulating the compositional changes in the lungs. Consistent with histological assessment and gene expression analysis, our study suggests that remodeling of the extracellular matrix components may present promising markers for objective recognition of the premetastatic niche, independent of conventional clinical information. Cancer Res; 77(2); 247-56. ©2016 AACR.


Asunto(s)
Neoplasias Pulmonares/secundario , Neoplasias Mamarias Animales/secundario , Metástasis de la Neoplasia/patología , Lesiones Precancerosas/patología , Espectrometría Raman/métodos , Animales , Línea Celular Tumoral , Femenino , Humanos , Ratones , Ratones Desnudos , Procesamiento de Señales Asistido por Computador , Microambiente Tumoral/fisiología
6.
J Feline Med Surg ; 18(12): 1003-1012, 2016 12.
Artículo en Inglés | MEDLINE | ID: mdl-26460079

RESUMEN

OBJECTIVES: The aim of the study was to investigate prognostic factors in feline mammary gland neoplasms, correlating them with overall survival (OS). METHODS: Fifty-six primary malignant mammary gland neoplasms and 16 metastatic lymph nodes from 37 female cats were analyzed. Clinical staging, histologic type and grade, and immunohistochemistry for Ki-67, progesterone and estrogen receptor, human epidermal growth factor receptor type 2 (HER-2), cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) were evaluated. Follow-up was performed in order to correlate prognostic factors with OS. RESULTS: Lymph node metastasis was found in 35% of cases. Clinical stage III, tubulopapillary carcinomas and histologic grade II cases prevailed in the study. Most neoplasms were positive for hormonal receptors, negative for HER-2 overexpression and presented VEGF overexpression. Immunoreactivity for Ki-67 (P = 0.046) and COX-2 (P = 0.007) was higher in metastases than in primary tumors. COX-2 (P = 0.089), HER-2 (P = 0.012) and histologic grade (P = 0.080) were correlated with OS. CONCLUSIONS AND RELEVANCE: The data suggest that inhibition of ovarian hormones and COX-2 may represent a therapeutic option for malignant feline mammary gland neoplasms. When evaluating disease progression, COX-2 scores and Ki-67 index should be analyzed in primary tumors and metastases. Histologic grade, HER-2 status and COX-2 scores were found to have a direct influence on OS. Prognostic factors allow for a better understanding of disease outcome in a condition that is characterized by a poor prognosis. The present work highlights the need for further studies on endocrine therapy and COX-2 inhibitors, which could influence OS.


Asunto(s)
Biomarcadores/metabolismo , Enfermedades de los Gatos/enzimología , Ciclooxigenasa 2/biosíntesis , Neoplasias Mamarias Animales/enzimología , Animales , Brasil , Enfermedades de los Gatos/mortalidad , Enfermedades de los Gatos/patología , Gatos , Supervivencia sin Enfermedad , Femenino , Inmunohistoquímica/veterinaria , Metástasis Linfática , Neoplasias Mamarias Animales/mortalidad , Neoplasias Mamarias Animales/secundario , Pronóstico , Estudios Retrospectivos
7.
PLoS One ; 10(7): e0134458, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26222311

RESUMEN

The tumor microenvironment encompasses several stressful conditions for cancer cells such as hypoxia, oxidative stress and pH alterations. Galectin-3, a well-studied member of the beta-galactoside-binding animal family of lectins has been implicated in multiple steps of metastasis as cell-cell and cell-ECM adhesion, promotion of angiogenesis, cell proliferation and resistance to apoptosis. However, both its aberrantly up- and down-regulated expression was observed in several types of cancer. Thus, the mechanisms that regulate galectin-3 expression in neoplastic settings are not clear. In order to demonstrate the putative role of hypoxia in regulating galectin-3 expression in canine mammary tumors (CMT), in vitro and in vivo studies were performed. In malignant CMT cells, hypoxia was observed to induce expression of galectin-3, a phenomenon that was almost completely prevented by catalase treatment of CMT-U27 cells. Increased galectin-3 expression was confirmed at the mRNA level. Under hypoxic conditions the expression of galectin-3 shifts from a predominant nuclear location to cytoplasmic and membrane expressions. In in vivo studies, galectin-3 was overexpressed in hypoxic areas of primary tumors and well-established metastases. Tumor hypoxia thus up-regulates the expression of galectin-3, which may in turn increase tumor aggressiveness.


Asunto(s)
Galectina 3/metabolismo , Neoplasias Mamarias Experimentales/metabolismo , Animales , Línea Celular Tumoral , Progresión de la Enfermedad , Perros , Femenino , Galectina 3/genética , Transportador de Glucosa de Tipo 1/genética , Transportador de Glucosa de Tipo 1/metabolismo , Hipoxia/metabolismo , Neoplasias Mamarias Animales/genética , Neoplasias Mamarias Animales/metabolismo , Neoplasias Mamarias Animales/secundario , Neoplasias Mamarias Experimentales/genética , Neoplasias Mamarias Experimentales/secundario , Ratones Desnudos , ARN Mensajero/genética , ARN Mensajero/metabolismo , ARN Neoplásico/genética , ARN Neoplásico/metabolismo , Trasplante Heterólogo , Microambiente Tumoral , Regulación hacia Arriba
8.
Nanoscale ; 7(2): 500-10, 2015 Jan 14.
Artículo en Inglés | MEDLINE | ID: mdl-25408159

RESUMEN

Tumor associated macrophages (TAMs) can modify the tumor microenvironment to create a pro-tumor niche. Manipulation of the TAM phenotype is a novel, potential therapeutic approach to engage anti-cancer immunity. siRNA is a molecular tool for knockdown of specific mRNAs that is tunable in both strength and duration. The use of siRNA to reprogram TAMs to adopt an immunogenic, anti-tumor phenotype is an attractive alternative to ablation of this cell population. One current difficulty with this approach is that TAMs are difficult to specifically target and transfect. We report here successful utilization of novel mannosylated polymer nanoparticles (MnNP) that are capable of escaping the endosomal compartment to deliver siRNA to TAMs in vitro and in vivo. Transfection with MnNP-siRNA complexes did not significantly decrease TAM cell membrane integrity in culture, nor did it create adverse kidney or liver function in mice, even at repeated doses of 5 mg kg(-1). Furthermore, MnNP effectively delivers labeled nucleotides to TAMs in mice with primary mammary tumors. We also confirmed TAM targeting in the solid tumors disseminated throughout the peritoneum of ovarian tumor bearing mice following injection of fluorescently labeled MnNP-nucleotide complexes into the peritoneum. Finally, we show enhanced uptake of MnNP in lung metastasis associated macrophages compared to untargeted particles when using an intubation delivery method. In summary, we have shown that MnNP specifically and effectively deliver siRNA to TAMs in vivo.


Asunto(s)
Materiales Biocompatibles/química , Portadores de Fármacos/química , Endosomas/metabolismo , Manosa/química , Nanopartículas/química , ARN Interferente Pequeño/metabolismo , Animales , Materiales Biocompatibles/metabolismo , Línea Celular Tumoral , Supervivencia Celular , Técnicas de Cocultivo , Femenino , Colorantes Fluorescentes/química , Pulmón/metabolismo , Pulmón/patología , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/terapia , Macrófagos/citología , Macrófagos/metabolismo , Macrófagos/trasplante , Neoplasias Mamarias Animales/patología , Neoplasias Mamarias Animales/secundario , Neoplasias Mamarias Animales/terapia , Manosa/metabolismo , Ratones , Ratones Endogámicos C57BL , Microscopía Fluorescente , Nanopartículas/metabolismo , Neoplasias Ováricas/metabolismo , Neoplasias Ováricas/patología , Polímeros/química , ARN Interferente Pequeño/química , ARN Interferente Pequeño/uso terapéutico , Trasplante Homólogo , Microambiente Tumoral
9.
Chem Pharm Bull (Tokyo) ; 60(9): 1146-54, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22976323

RESUMEN

Docetaxel (DTX) is hydrophobic, and its available formulations (Taxotere(®) & Duopafei(®)) require Tween80 and ethanol vehicle to allow parental administration. DTX-loaded poly(D,L-lactide)-b-polyethylene glycol-methoxy (mPEG-b-PDLLA) polymeric micelle (PM) is a Tween80-free formulation of DTX, which has been extensively studied but rarely involved with industrialization issues. In this work, novel DTX-PM with improved loading capacity and well-reconsitution ability was developed. The freeze-dried DTX-PM was analyzed by HPLC, transmission electron microscopy (TEM) and dynamic light scattering (DLS) to determine the DTX loading, micelle morphology and size respectively. The in vitro cytotoxic activity of DTX-PM in 4T1 cells was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and the corresponding in vivo study was assessed in BALB/c mice bearing 4T1 tumor through intravenous administration. The DTX-loading and efficiency into the micelles were 20.74±1.23% and 93.7±1.03% respectively, which was much higher than ever reported PM. The DTX-PM was spherical with a mean particle size of 16.62±0.31 nm, which suggested that they were able to selectively accumulate in solid tumors by enhanced permeability and retention (EPR) effect. Another important characteristic of DTX-PM is the long term storage and reuses as aqueous injection solution. Many kinds of lyoprotectants were also investigated and dextrose was found to an excellent one. Compared with Duopafei(®), DTX-PM showed better cytotoxicity and anti-metastasis ability against 4T1 cells in vitro and in vivo. In conclusion, DTX-PM significantly enhanced drug-loading capacity of DTX and had well-reconsitution ability, which could be a promising drug delivery system for clinic.


Asunto(s)
Antineoplásicos/administración & dosificación , Antineoplásicos/uso terapéutico , Portadores de Fármacos/química , Neoplasias Mamarias Animales/secundario , Metástasis de la Neoplasia/prevención & control , Taxoides/administración & dosificación , Taxoides/uso terapéutico , Animales , Antineoplásicos/farmacología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Docetaxel , Cobayas , Hemólisis/efectos de los fármacos , Ácido Láctico/química , Neoplasias Mamarias Animales/tratamiento farmacológico , Neoplasias Mamarias Animales/patología , Ratones , Ratones Endogámicos BALB C , Micelas , Metástasis de la Neoplasia/patología , Poliésteres , Polietilenglicoles/química , Polímeros/química , Ratas , Taxoides/farmacología
10.
Int J Dev Biol ; 55(7-9): 823-34, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22161838

RESUMEN

Galectin-3 is involved both in facilitating detachment of cells from primary tumour sites and favouring cancer cell adhesion and survival to anoikis in the blood stream. The mechanisms behind these apparently contradictory roles of the lectin have not yet been resolved. In order to investigate possible interplays between galectin-3 and its ligands underlying their role in the metastatic process, we examined mucin-1 (MUC1) and epidermal growth factor receptor (EGFR), well-known galectin-3 ligands, as well as galectin-3-binding site expression in a series of spontaneous canine malignant mammary tumours (CMMT) and a metastatic CMMT cell line. Despite the fact that CMMT cells expressed MUC1 and EGFR homogeneously over their plasma membrane, intravascular tumour cells, positive for galectin-3, expressed MUC1 and EGFR in a more focal membrane localization. Moreover, MUC1 overexpression in primary CMMT was present in parallel with down-regulation of galectin-3. Furthermore, in the CMT-U27 cell line, galectin-3 knock-down led to increased MUC1 expression, while MUC1 knock-down led to down-regulation of the lectin. Finally, removal of sialic acid from both CMMT and CMT-U27 xenograft samples exposed galectin-3-ligands throughout the tumour tissue, whereas these ligands were only present in galectin-3-positive invading cells in untreated samples. Interestingly indeed, we show that in vessel-invading cells, there is interaction between galectin-3 and the T antigen in vivo. We therefore hypothesized that loss of galectin-3 and sialylation-related masking of its ligands, in conjunction with their overexpression in specific tumour cell subpopulations, are crucial in regulating adhesive/de-adhesive events in the progression and invasive capacity of metastatic cells.


Asunto(s)
Enfermedades de los Perros/etiología , Enfermedades de los Perros/metabolismo , Galectina 3/metabolismo , Neoplasias Mamarias Animales/etiología , Neoplasias Mamarias Animales/metabolismo , Animales , Antígenos de Carbohidratos Asociados a Tumores/metabolismo , Sitios de Unión , Adhesión Celular , Línea Celular Tumoral , Supervivencia Celular , Progresión de la Enfermedad , Enfermedades de los Perros/patología , Perros , Regulación hacia Abajo , Receptores ErbB/genética , Receptores ErbB/metabolismo , Retroalimentación Fisiológica , Femenino , Galectina 3/genética , Inmunohistoquímica , Ligandos , Neoplasias Mamarias Animales/patología , Neoplasias Mamarias Animales/secundario , Ratones , Ratones Desnudos , Modelos Biológicos , Mucina-1/genética , Mucina-1/metabolismo , Invasividad Neoplásica , Ácidos Siálicos/metabolismo , Trasplante Heterólogo , Regulación hacia Arriba
11.
J Virol ; 85(20): 10440-50, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21813611

RESUMEN

Vesicular stomatitis virus (VSV), a negative-strand RNA rhabdovirus, preferentially replicates in and eradicates transformed versus nontransformed cells and is thus being considered for use as a potential anticancer treatment. The genetic malleability of VSV also affords an opportunity to develop more potent agents that exhibit increased therapeutic activity. The tumor suppressor p53 has been shown to exert potent antitumor properties, which may in part involve stimulating host innate immune responses to malignancies. To evaluate whether VSV expressing p53 exhibited enhanced oncolytic action, the murine p53 (mp53) gene was incorporated into recombinant VSVs with or without a functional viral M gene-encoded protein that could either block (VSV-mp53) or enable [VSV-M(mut)-mp53] host mRNA export following infection of susceptible cells. Our results indicated that VSV-mp53 and VSV-M(mut)-mp53 expressed high levels of functional p53 and retained the ability to lyse transformed versus normal cells. In addition, we observed that VSV-ΔM-mp53 was extremely attenuated in vivo due to p53 activating innate immune genes, such as type I interferon (IFN). Significantly, immunocompetent animals with metastatic mammary adenocarcinoma exhibited increased survival following treatment with a single inoculation of VSV-ΔM-mp53, the mechanisms of which involved enhanced CD49b+ NK and tumor-specific CD8+ T cell responses. Our data indicate that VSV incorporating p53 could provide a safe, effective strategy for the design of VSV oncolytic therapeutics and VSV-based vaccines.


Asunto(s)
Virus Oncolíticos/crecimiento & desarrollo , Proteína p53 Supresora de Tumor/metabolismo , Vesiculovirus/crecimiento & desarrollo , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/secundario , Animales , Modelos Animales de Enfermedad , Femenino , Neoplasias Mamarias Animales/secundario , Neoplasias Mamarias Animales/terapia , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Viroterapia Oncolítica/métodos , Virus Oncolíticos/genética , Virus Oncolíticos/patogenicidad , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Enfermedades de los Roedores/terapia , Resultado del Tratamiento , Proteína p53 Supresora de Tumor/genética , Vesiculovirus/genética , Vesiculovirus/patogenicidad
12.
EMBO J ; 29(24): 4106-17, 2010 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-21076392

RESUMEN

Inflammation and hypoxia are known to promote the metastatic progression of tumours. The CCAAT/enhancer-binding protein-δ (C/EBPδ, CEBPD) is an inflammatory response gene and candidate tumour suppressor, but its physiological role in tumourigenesis in vivo is unknown. Here, we demonstrate a tumour suppressor function of C/EBPδ using transgenic mice overexpressing the Neu/Her2/ERBB2 proto-oncogene in the mammary gland. Unexpectedly, this study also revealed that C/EBPδ is necessary for efficient tumour metastasis. We show that C/EBPδ is induced by hypoxia in tumours in vivo and in breast tumour cells in vitro, and that C/EBPδ-deficient cells exhibit reduced glycolytic metabolism and cell viability under hypoxia. C/EBPδ supports CXCR4 expression. On the other hand, C/EBPδ directly inhibits expression of the tumour suppressor F-box and WD repeat-domain containing 7 gene (FBXW7, FBW7, AGO, Cdc4), encoding an F-box protein that promotes degradation of the mammalian target of rapamycin (mTOR). Consequently, C/EBPδ enhances mTOR/AKT/S6K1 signalling and augments translation and activity of hypoxia-inducible factor-1α (HIF-1α), which is necessary for hypoxia adaptation. This work provides new insight into the mechanisms by which metastasis-promoting signals are induced specifically under hypoxia.


Asunto(s)
Proteína delta de Unión al Potenciador CCAAT/metabolismo , Proteínas F-Box/biosíntesis , Regulación de la Expresión Génica , Hipoxia , Neoplasias Mamarias Animales/secundario , Metástasis de la Neoplasia/patología , Ubiquitina-Proteína Ligasas/biosíntesis , Animales , Proliferación Celular , Supervivencia Celular , Células Cultivadas , Proteína 7 que Contiene Repeticiones F-Box-WD , Glucólisis , Neoplasias Mamarias Animales/patología , Neoplasias Mamarias Animales/fisiopatología , Ratones , Ratones Transgénicos , Metástasis de la Neoplasia/fisiopatología
13.
EMBO Mol Med ; 2(6): 211-30, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20535745

RESUMEN

JunD regulates genes involved in antioxidant defence. We took advantage of the chronic oxidative stress resulting from junD deletion to examine the role of reactive oxygen species (ROS) in tumour development. In a model of mammary carcinogenesis, junD inactivation increased tumour incidence and revealed an associated reactive stroma. junD-inactivation in the stroma was sufficient to shorten tumour-free survival rate and enhance metastatic spread. ROS promoted conversion of fibroblasts into highly migrating myofibroblasts through accumulation of the hypoxia-inducible factor (HIF)-1alpha transcription factor and the CXCL12 chemokine. Accordingly, treatment with an antioxidant reduced the levels of HIF and CXCL12 and numerous myofibroblast features. CXCL12 accumulated in the stroma of HER2-human breast adenocarcinomas. Moreover, HER2 tumours exhibited a high proportion of myofibroblasts, which was significantly correlated to nodal metastases. Interestingly, this subset of tumours exhibited a significant nuclear exclusion of JunD and revealed an associated oxido-reduction signature, further demonstrating the relevance of our findings in human cancers. Collectively, our data uncover a new mechanism by which oxidative stress increases the migratory properties of stromal fibroblasts, which in turn potentiate tumour dissemination.


Asunto(s)
Neoplasias de la Mama/secundario , Fibroblastos/efectos de los fármacos , Neoplasias Mamarias Animales/secundario , Metástasis de la Neoplasia/patología , Estrés Oxidativo , Proteínas Proto-Oncogénicas/deficiencia , Especies Reactivas de Oxígeno/toxicidad , Animales , Neoplasias de la Mama/patología , Diferenciación Celular , Línea Celular , Quimiocina CXCL12/metabolismo , Femenino , Histocitoquímica , Humanos , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Inmunohistoquímica , Incidencia , Locomoción , Neoplasias Mamarias Animales/patología , Ratones , Ratones Noqueados , Microscopía , Microscopía Fluorescente , Modelos Biológicos , Proteínas Proto-Oncogénicas/fisiología , Proteínas Proto-Oncogénicas c-jun , Análisis de Supervivencia
14.
J Natl Cancer Inst ; 100(9): 649-62, 2008 May 07.
Artículo en Inglés | MEDLINE | ID: mdl-18445820

RESUMEN

BACKGROUND: Resistance of tumors to cell death signals poses a complex clinical problem. We explored the therapeutic potential and in vivo toxicity of a combination of bortezomib, a proteasome inhibitor, and MD5-1, a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor (DR5) agonist monoclonal antibody, in mouse carcinomas. METHODS; Mice bearing Renca-FLAG (renal) or 4T1 (mammary) tumors were treated with bortezomib and/or MD5-1 and examined for lung metastases (Renca-FLAG: n = 93; 4T1: n = 40) or monitored for survival (Renca-FLAG: n = 143). Toxicity was assessed by histopathology and hematology. Viability and apoptotic signaling in Renca-FLAG and 4T1 cells treated with bortezomib alone or in combination with TRAIL were analyzed using 3-[4,5-dimethyiazol-2-yl-5]-[3-carboxymethyloxyphenyl]-2-[4-sulfophenyl]-2H tetrazolium assay and by measuring mitochondrial membrane depolarization and caspase-8 and caspase-3 activation. All statistical tests were two-sided. RESULTS: Bortezomib (20 nM) sensitized Renca-FLAG and 4T1 cells to TRAIL-mediated apoptosis (mean percent decrease in numbers of viable cells, bortezomib + TRAIL vs TRAIL: Renca-FLAG, 95% vs 34%, difference = 61%, 95% confidence interval [CI] = 52% to 69%, P < .001; 4T1, 85% vs 20%, difference = 65%, 95% CI = 62% to 69%, P < .001). Sensitization involved activation of caspase-8 and caspase-3 but not mitochondrial membrane depolarization, suggesting an amplified signaling of the extrinsic cell death pathway. Treatment with bortezomib and MD5-1 reduced lung metastases in mice carrying Renca and 4T1 tumors (mean number of metastases, bortezomib + MD5-1 vs MD5-1: Renca-FLAG, 1 vs 8, difference = 7, 95% CI = 5 to 9, P < .001; 4T1, 1 vs 12, difference = 11, 95% CI = 9 to 12, P < .001) and increased median survival of mice bearing Renca-FLAG tumors (bortezomib + MD5-1 vs bortezomib + control isotype antibody: 22 of 30 [73%] were still alive at day 180 vs median survival of 42 days [95% CI = 41 to 44 days, P < .001]) in the absence of obvious toxicity. CONCLUSION: Bortezomib combined with DR5 agonist monoclonal antibody may be a useful treatment for metastatic solid tumors.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Anticuerpos Monoclonales/farmacología , Antineoplásicos/farmacología , Ácidos Borónicos/farmacología , Neoplasias Renales/tratamiento farmacológico , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Mamarias Animales/tratamiento farmacológico , Pirazinas/farmacología , Receptores del Ligando Inductor de Apoptosis Relacionado con TNF/agonistas , Ligando Inductor de Apoptosis Relacionado con TNF/metabolismo , Adenocarcinoma/secundario , Animales , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Apoptosis/efectos de los fármacos , Bortezomib , Caspasa 3/metabolismo , Caspasa 8/metabolismo , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Femenino , Citometría de Flujo , Humanos , Immunoblotting , Neoplasias Renales/patología , Neoplasias Pulmonares/secundario , Neoplasias Mamarias Animales/secundario , Ratones , Ratones Endogámicos BALB C , Membranas Mitocondriales/metabolismo , Inhibidores de Proteasas/farmacología , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Transducción de Señal/efectos de los fármacos
15.
BMC Cancer ; 7: 225, 2007 Dec 18.
Artículo en Inglés | MEDLINE | ID: mdl-18088404

RESUMEN

BACKGROUND: Carcinomas of unknown primary site (CUP) are epithelial malignancies revealed by metastatic lesions in the absence of any detectable primary tumor. Although they often adopt an aggressive clinical pattern, their basic biology remains poorly understood. Laboratory research on their biology have been hampered so far by the absence of cell lines representative of CUPs. METHODS: We attempted xenografts of CUP clinical specimens in immunodeficient mice and subsequent in vitro culture of transplanted malignant cells. Whenever possible, malignant xenografted or cultured cells were characterized by microsatellite genotyping, immunohistology, electron microscopy, multifish chromosome analysis and search of TP 53 gene mutations. RESULTS: Successful xenografts were achieved in 2 cases out of 4. One of them (Capi1) was lost after 3 passages whereas the other one (Capi3) has been adapted to in vitro culture and is currently available to the scientific community with reliable identification based on microsatellite genotyping. Both Capi1 and Capi3 have histological characteristics of adenocarcinomas and display intense expression of EMA, CEA and cytokeratin 7. Multifish chromosome analysis demonstrated a translocation involving chromosomes 4 and 21 in both specimens. Distinct rare missense mutations of the TP53 gene were detected in Capi1 (codon 312) and Capi3 (codon 181); the codon 181 mutation is consistent with a previously reported similar finding in a small series of CUP specimens. Finally, intense membrane expression of c-kit was recorded in Capi3. CONCLUSION: Our data suggest that xenografted tumors can be obtained from a substantial fraction of CUP clinical specimens. The hypothesis of a preferential association of CUPs with TP 53 mutations of codon 181 deserves further investigations. The Capi3 cell line will be a useful tool for assessment of novel c-kit inhibitors.


Asunto(s)
Adenocarcinoma/genética , Adenocarcinoma/secundario , Regulación Neoplásica de la Expresión Génica , Trasplante de Neoplasias/patología , Neoplasias Primarias Desconocidas/genética , Neoplasias Primarias Desconocidas/patología , Trasplante Heterólogo/patología , Adenocarcinoma/patología , Animales , Neoplasias Óseas/secundario , Línea Celular Tumoral , Cromosomas Humanos Par 21/genética , Cromosomas Humanos Par 4/genética , Femenino , Genes Relacionados con las Neoplasias/genética , Genes p53/genética , Humanos , Inmunohistoquímica , Masculino , Neoplasias Mamarias Animales/secundario , Ratones , Ratones Desnudos , Ratones SCID , Repeticiones de Microsatélite/genética , Microscopía Electrónica , Mutación Missense/genética , Neoplasias Pleurales/secundario , Proteínas Proto-Oncogénicas c-kit/genética , Proteínas Proto-Oncogénicas c-kit/metabolismo , Neoplasias Cutáneas/secundario
16.
Int J Exp Pathol ; 88(5): 351-60, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17877537

RESUMEN

The murine mammary carcinoma 4T1 causes a leukemoid reaction with profound granulocytosis coincident with the production of tumour-derived growth factors. Here, we study the evolving cellular landscape of primary tumours and metastatic tumour foci and correlate haematopoietic cell infiltration with the production of tumour-derived chemokines. Flow cytometric analysis of enzyme digested primary tumours at different times after transplantation revealed a progressively increasing CD45(+) haematopoietic cell infiltrate consisting predominantly of CD11b(+) myeloid cells. Most of these cells had an F4/80(+)/CD11c(+) phenotype, many of which also stained Gr-1(+). Smaller numbers of Gr-1(+)CD11b(+) granulocytes and lymphoid cells were also identified. Progressive increases in Gr-1(+) granulocytes were observed in enzymatic digests of livers and lungs with metastatic tumour foci. Cultured 4T1 tumour cells expressed mRNA transcripts for the myeloid cell chemokines RANTES, MCP-1 and KC, and enzymatically digested cells from primary 4T1 tumours partially depleted of CD45(+) cells expressed transcripts for these chemokines and also MIP-1alpha and MIP-1beta. These data demonstrate that 4T1 tumour-bearing mice have mixed myeloid cell infiltrates of primary tumours and granulocytic infiltrates of metastatic organs. This pathologic presentation correlated with the expression of tumour-derived chemokines.


Asunto(s)
Neoplasias de la Mama/patología , Neoplasias de la Mama/secundario , Neoplasias Hepáticas/secundario , Neoplasias Pulmonares/secundario , Neoplasias Mamarias Animales/patología , Células Mieloides/patología , Animales , Neoplasias de la Mama/inmunología , Antígeno CD11b/inmunología , Quimiocina CCL2/genética , Quimiocina CCL3/genética , Quimiocina CCL4/genética , Quimiocina CCL5/genética , Quimiocina CXCL1/genética , Progresión de la Enfermedad , Femenino , Citometría de Flujo/métodos , Expresión Génica , Humanos , Inmunofenotipificación , Reacción Leucemoide , Neoplasias Hepáticas/inmunología , Neoplasias Hepáticas/patología , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/patología , Neoplasias Mamarias Animales/inmunología , Neoplasias Mamarias Animales/secundario , Ratones , Ratones Endogámicos BALB C , Células Mieloides/inmunología , Trasplante de Neoplasias , ARN Mensajero/análisis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células Tumorales Cultivadas
17.
Proc Natl Acad Sci U S A ; 104(16): 6696-701, 2007 Apr 17.
Artículo en Inglés | MEDLINE | ID: mdl-17420453

RESUMEN

Here, we report the identification of a metastasis promoting factor by a forward genetic screen in mice. A retroviral cDNA library was introduced into the nonmetastatic cancer cell line 168FARN, which was then orthotopically transplanted into mouse mammary fat pads, followed by selection for cells that metastasize to the lung. The genes encoding the disulfide isomerase ERp5 and beta-catenin were found to promote breast cancer invasion and metastasis. Disulfide isomerases (thiol isomerases), which catalyze disulfide bond formation, reduction, and isomerization, have not previously been implicated in cancer cell signaling and tumor metastasis. Overexpression of ERp5 promotes both in vitro migration and invasion and in vivo metastasis of breast cancer cells. These effects were shown to involve activation of ErbB2 and phosphoinositide 3-kinase (PI3K) pathways through dimerization of ErbB2. Activation of ErbB2 and PI3K subsequently stimulates RhoA and beta-catenin, which mediate the migration and invasion of tumor cells. Inhibition of ErbB2 and PI3K reverses the phenotypes induced by ERp5. Finally, ERp5 was shown to be up-regulated in human surgical samples of invasive breast cancers. These data identify a link between disulfide isomerases and tumor development, and provide a mechanism that modulates ErbB2 and PI3K signaling in the promotion of cancer progression.


Asunto(s)
Neoplasias Mamarias Animales/genética , Neoplasias Mamarias Animales/secundario , Selección Genética , Animales , Línea Celular Tumoral , Femenino , Humanos , Neoplasias Mamarias Animales/enzimología , Neoplasias Mamarias Animales/patología , Ratones , Proteína Disulfuro Isomerasas/genética , Proteína Disulfuro Isomerasas/fisiología
18.
Tijdschr Diergeneeskd ; 130(1): 2-7, 2005 Jan 01.
Artículo en Holandés | MEDLINE | ID: mdl-15656111

RESUMEN

A 14-year-old Haflinger mare was presented with a wound on the right metatarsus which it had sustained 3 years earlier. The wound had never completely healed but had only recently become a problem. Over a period of several months, the wound became larger, produced a lot of exudate, and the horse became lame on the affected limb. Clinical examination and radiographs failed to reveal the cause of the deterioration. Histological evaluation of tissue removed during debridement of the wound revealed squamous cell carcinoma. Because the tumour had already invaded the bone, the prognosis was unfavourable and the horse was euthanised. Necropsy showed the tumour to have metastasised to the right inguinal area and the adjacent mammary gland.


Asunto(s)
Neoplasias Óseas/veterinaria , Carcinoma de Células Escamosas/veterinaria , Enfermedades de los Caballos/diagnóstico , Neoplasias Cutáneas/veterinaria , Cicatrización de Heridas , Animales , Neoplasias Óseas/diagnóstico , Neoplasias Óseas/patología , Carcinoma de Células Escamosas/diagnóstico , Carcinoma de Células Escamosas/patología , Resultado Fatal , Femenino , Enfermedades de los Caballos/patología , Caballos , Inmunohistoquímica/veterinaria , Cojera Animal/diagnóstico , Cojera Animal/patología , Neoplasias Mamarias Animales/secundario , Metatarso/lesiones , Invasividad Neoplásica , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/patología
19.
Breast Cancer Res ; 6(4): R316-21, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15217498

RESUMEN

INTRODUCTION: Overexpression of cyclooxygenase (COX-2) is commonly observed in human cancers. In a murine model of metastatic breast cancer, we observed that COX-2 expression and enzyme activity were associated with enhanced tumorigenic and metastatic potential. In contrast to the high COX-2 expression in metastatic tumors, transplantation of poorly tumorigenic tumor cell lines to syngeneic mice results in less COX-2 expression and less COX-2 activity in vivo. Aberrant CpG island methylation, and subsequent silencing of the COX-2 promoter, has been observed in human cancer cell lines and in some human tumors of the gastrointestinal tract. METHODS: Using bisulfite modification and a methylation-specific PCR, we examined the methylation status of the COX-2 promoter in a series of four closely-related murine mammary tumors differing in COX-2 expression and metastatic potential. RESULTS: We showed that line 410, which does not express COX-2 in vivo, exhibited evidence of promoter methylation. Interestingly, the metastatic counterpart of this cell (line 410.4) displayed only the unmethylated COX-2 promoter, as did two additional cell lines (lines 66.1 and 67). The methylation patterns observed in vitro were maintained when these murine mammary tumor lines were transplanted to syngeneic mice. Treatment with the DNA demethylating agent 5-aza-deoxycytidine increased COX-2 mRNA, increased protein and increased enzyme activity (prostaglandin synthesis). CONCLUSIONS: These results indicate that COX-2 promoter methylation may be one mechanism by which tumor cells regulate COX-2 expression. Upregulation of COX-2 expression in closely related metastatic lesions versus nonmetastatic lesions may represent a shift towards the unmethylated phenotype.


Asunto(s)
Neoplasias de la Mama/enzimología , Neoplasias de la Mama/genética , Metilación de ADN , Regulación Enzimológica de la Expresión Génica/genética , Regulación Neoplásica de la Expresión Génica/genética , Isoenzimas/genética , Regiones Promotoras Genéticas/genética , Prostaglandina-Endoperóxido Sintasas/genética , Animales , Neoplasias de la Mama/secundario , Línea Celular Tumoral , Ciclooxigenasa 2 , ADN de Neoplasias/metabolismo , Modelos Animales de Enfermedad , Humanos , Isoenzimas/fisiología , Neoplasias Mamarias Animales/enzimología , Neoplasias Mamarias Animales/genética , Neoplasias Mamarias Animales/secundario , Proteínas de la Membrana , Ratones , Prostaglandina-Endoperóxido Sintasas/fisiología
20.
J Wildl Dis ; 39(1): 241-3, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12685092

RESUMEN

Two histologic types of mammary cancer were encountered in an aged captive California sea lion (Zalophus californianus). A cancer with myoepithelial cell proliferation, which had metastasized to distant viscera, was located in the left cranial mammary region. Another cancer without myoepithelial cell proliferation was located in the right posterior mammary region, formed secondary nodules, and had metastasized to a regional lymph node. The presence of two different neoplasms in this sea lion is unusual.


Asunto(s)
Carcinoma/veterinaria , Neoplasias Mamarias Animales/diagnóstico , Mioepitelioma/veterinaria , Neoplasias Primarias Múltiples/veterinaria , Leones Marinos , Animales , Animales de Zoológico , Carcinoma/diagnóstico , Carcinoma/patología , Resultado Fatal , Femenino , Inmunohistoquímica/veterinaria , Metástasis Linfática , Neoplasias Mamarias Animales/patología , Neoplasias Mamarias Animales/secundario , Mioepitelioma/diagnóstico , Mioepitelioma/patología , Neoplasias Primarias Múltiples/diagnóstico , Neoplasias Primarias Múltiples/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA